InspireMD, Inc. (NSPR)
InspireMD, Inc. develops and commercializes MicroNet stent platform technology for vascular and coronary diseases. Their products include CGuard and MGuard Prime embolic prevention systems, sold through distributors in Europe, Latin America, the Middle East, and Asia Pacific.
Company Overview
InspireMD is a medical device innovator focused on embolic prevention through its proprietary MicroNet stent technology, offering solutions like CGuard and MGuard Prime to address critical vascular and coronary diseases in international markets, presenting a high-growth opportunity in a specialized medical niche.
Investment Thesis
InspireMD presents a compelling investment opportunity due to its innovative MicroNet stent technology and focus on the growing embolic prevention market. The company's CGuard and MGuard Prime systems address critical needs in vascular and coronary disease treatment, offering improved patient outcomes. With a market capitalization of $0.07 billion, InspireMD has significant upside potential as it expands its market reach and introduces new products like PVGuard. The company's established distribution network in Europe, Latin America, the Middle East, and Asia Pacific provides a solid foundation for revenue growth. While the company currently has a negative P/E ratio of -2.77 and a negative profit margin of -593.9%, strategic investments in R&D and market penetration should drive long-term profitability. The company's beta of 0.90 suggests lower volatility than the overall market.
Key Highlights
- Market Cap of $0.07B indicates a small-cap company with potential for high growth.
- Gross Margin of 24.9% demonstrates the company's ability to generate revenue above the cost of goods sold.
- Beta of 0.90 suggests lower volatility compared to the broader market.
- Focus on proprietary MicroNet stent platform technology provides a unique selling proposition.
- Presence in Europe, Latin America, Middle East, and Asia Pacific offers diversified revenue streams.
Competitors
Strengths
- Proprietary MicroNet stent technology.
- Established presence in Europe, Latin America, Middle East, and Asia Pacific.
- Focus on embolic prevention.
- Developing new products like PVGuard.
Weaknesses
- Negative P/E ratio and profit margin.
- Reliance on distributors for sales.
- Limited market share compared to larger competitors.
- Small market capitalization.
Catalysts
- Upcoming: Regulatory approvals for PVGuard in key markets.
- Ongoing: Clinical studies demonstrating the efficacy of CGuard and MGuard Prime.
- Ongoing: Expansion of the sales force and distribution network.
- Ongoing: Strategic partnerships with hospitals and medical centers.
Risks
- Potential: Competition from established medical device companies.
- Potential: Product liability claims.
- Ongoing: Regulatory changes affecting medical device approvals.
- Ongoing: Dependence on distributors for sales.
Growth Opportunities
- Expansion into New Geographic Markets: InspireMD has the opportunity to expand its market presence beyond its current focus regions of Europe, Latin America, the Middle East, and Asia Pacific. Entering North America, particularly the United States, represents a significant growth opportunity given the large market size and established healthcare infrastructure. This expansion would require regulatory approvals and strategic partnerships, but could substantially increase revenue and market share. Timeline: 2-3 years. Market Size: Multi-billion dollar market.
- Development and Commercialization of PVGuard: The company's PVGuard, a MicroNet mesh sleeve and self-expandable stent for peripheral vascular applications, represents a significant growth opportunity. Successfully developing and commercializing PVGuard would allow InspireMD to expand its product portfolio and address a new segment of the vascular disease market. This would involve clinical trials, regulatory approvals, and establishing a distribution network for peripheral vascular specialists. Timeline: 3-5 years. Market Size: Hundreds of millions of dollars.
- Strategic Partnerships and Acquisitions: InspireMD can pursue strategic partnerships or acquisitions to expand its product offerings, market reach, and technological capabilities. Collaborating with other medical device companies or acquiring complementary technologies could accelerate growth and create synergies. This could involve licensing agreements, joint ventures, or mergers and acquisitions. Timeline: Ongoing. Market Size: Varies depending on the specific partnership or acquisition.
- Increased Adoption of CGuard and MGuard Prime: Driving increased adoption of its existing CGuard and MGuard Prime systems represents a key growth opportunity. This can be achieved through targeted marketing campaigns, clinical studies demonstrating the efficacy and safety of the devices, and expanding the sales force to reach more physicians and hospitals. Focusing on key opinion leaders and building strong relationships with healthcare providers will be crucial. Timeline: Ongoing. Market Size: Existing market with potential for increased penetration.
- Technological Advancements and Innovation: Continuous investment in research and development to enhance its MicroNet stent platform and develop new embolic prevention technologies is essential for long-term growth. This includes improving the design, materials, and delivery systems of its devices to enhance performance and patient outcomes. Staying at the forefront of technological innovation will allow InspireMD to maintain a competitive advantage and capture market share. Timeline: Ongoing. Market Size: Future market driven by technological advancements.
Opportunities
- Expansion into new geographic markets, particularly North America.
- Increased adoption of CGuard and MGuard Prime.
- Development and commercialization of PVGuard.
- Strategic partnerships and acquisitions.
Threats
- Competition from larger medical device companies.
- Regulatory hurdles and approval processes.
- Economic downturns affecting healthcare spending.
- Product liability claims.
Competitive Advantages
- Proprietary MicroNet stent platform technology.
- Established distribution network in key international markets.
- Focus on embolic prevention in vascular and coronary procedures.
- Growing portfolio of products addressing unmet clinical needs.
About
InspireMD, Inc. was founded in 2005 with the vision of revolutionizing vascular and coronary disease treatment through innovative medical device solutions. The company's core technology revolves around its proprietary MicroNet stent platform, designed to enhance patient outcomes and address unmet clinical needs. InspireMD's flagship products include the CGuard Carotid Embolic Prevention System, specifically designed for carotid artery applications, and the MGuard Prime Embolic Protection System, used in patients with acute coronary syndromes, myocardial infarction, and saphenous vein graft interventions. These devices are engineered to prevent the release of emboli during vascular procedures, reducing the risk of stroke and other complications. InspireMD operates primarily in Europe, Latin America, the Middle East, and the Asia Pacific regions, selling its products through a network of local distributors. This strategic approach allows the company to effectively penetrate diverse markets and establish a strong presence in key geographic areas. While the company is headquartered in Tel Aviv-Yafo, Israel, it maintains a presence in Miami, IL. The company continues to invest in the development of new products, such as the PVGuard, aimed at expanding its portfolio and addressing additional applications in peripheral vascular disease. InspireMD's commitment to innovation and clinical excellence positions it as a key player in the embolic prevention market.
What They Do
- Develops MicroNet stent platform technology.
- Offers CGuard carotid embolic prevention system for carotid artery applications.
- Provides MGuard Prime embolic protection systems for acute coronary syndromes.
- Developing PVGuard for peripheral vascular applications.
- Sells products through local distributors.
- Focuses on treating vascular and coronary diseases.
Business Model
- Develops and manufactures medical devices.
- Sells products through a network of distributors.
- Generates revenue from sales of CGuard and MGuard Prime.
- Invests in research and development to create new products.
Industry Context
InspireMD operates in the medical device industry, specifically within the vascular and coronary disease treatment market. This market is characterized by continuous innovation and a growing demand for minimally invasive procedures. The embolic prevention systems segment is driven by the increasing prevalence of cardiovascular diseases and the need to reduce complications associated with vascular interventions. InspireMD competes with other medical device companies, including EDAP and HYPR, that offer similar solutions. The industry is subject to stringent regulatory requirements and requires significant investment in research and development. The global market for embolic protection devices is expected to grow, driven by technological advancements and an aging population.
Key Customers
- Hospitals and medical centers.
- Vascular surgeons.
- Interventional cardiologists.
- Patients with vascular and coronary diseases.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $3M | -$13M | $-0.17 |
| Q2 2025 | $2M | -$13M | $-0.26 |
| Q1 2025 | $2M | -$11M | $-0.22 |
| Q4 2024 | $2M | -$9M | $-0.19 |
Source: Company filings
Chart & Info
Price Chart
InspireMD, Inc. (NSPR) stock price: $1.93 (+0.07, +3.76%)
Why Bull
- •Recent insider buying suggests confidence in the company's future, which often indicates a positive outlook.
- •Community sentiment has shown increased interest, with discussions highlighting the potential of InspireMD's innovative technology.
- •Positive developments in clinical trials have generated optimism among investors, reinforcing the belief in long-term growth.
- •The medical device sector remains robust, with demand for advanced solutions driving interest in companies like InspireMD.
Why Bear
- •Concerns over regulatory hurdles have surfaced, as navigating the approval process can be lengthy and uncertain.
- •Community sentiment includes skepticism regarding the company's ability to scale its operations effectively in a competitive market.
- •Insider selling in the past may raise red flags about management's confidence in the company's short-term prospects.
- •Market perception is cautious, with some investors wary of the volatility typically associated with smaller biotech firms.
Latest News
-
Earnings Scheduled For November 4, 2025
benzinga · Nov 4, 2025
-
Earnings Scheduled For August 5, 2025
benzinga · Aug 5, 2025
-
Earnings Scheduled For November 12, 2024
benzinga · Nov 12, 2024
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Sep 27, 2022
Technical Analysis
Rationale
AI-generated technical analysis for NSPR including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss InspireMD, Inc. (NSPR) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for NSPR.
Make a Prediction
Set your price target for InspireMD, Inc. (NSPR), choose a timeframe, and track your prediction accuracy.
Current price: $1.93
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NSPR.
Price Targets
Wall Street price target analysis for NSPR.
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 4/100
Revenue grew only 13.0% YoY, suggesting the company is in a slower growth phase.
-
Gross Margin 6/100
Gross margin of 24.9% is acceptable but leaves limited room for R&D and marketing investment.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 3/100
Net insider selling of -$11.24M may indicate reduced confidence or routine diversification by executives.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates NSPR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Frequently Asked Questions
What does InspireMD, Inc. do?
InspireMD, Inc. is a medical device company that develops and commercializes proprietary MicroNet stent platform technology. Their primary focus is on creating solutions for the treatment of vascular and coronary diseases. The company's key products include the CGuard Carotid Embolic Prevention System and the MGuard Prime Embolic Protection System, designed to prevent emboli release during vascular procedures. InspireMD sells its products through a network of distributors in Europe, Latin America, the Middle East, and Asia Pacific, targeting hospitals, vascular surgeons, and interventional cardiologists.
Is NSPR stock a good buy?
NSPR stock presents a speculative investment opportunity with high potential but also significant risks. The company's innovative MicroNet stent technology and focus on the growing embolic prevention market are positive factors. However, the negative P/E ratio and profit margin indicate financial challenges. Investors should carefully consider the company's growth prospects, competitive landscape, and financial stability before investing. The potential for expansion into new markets and the development of new products like PVGuard could drive future growth, but execution is key.
What are the main risks for NSPR?
The main risks for InspireMD include intense competition from larger, more established medical device companies, which could limit its market share and pricing power. Regulatory hurdles and the lengthy approval processes for new medical devices pose another significant risk, potentially delaying product launches and increasing costs. The company's reliance on distributors for sales exposes it to potential disruptions in the distribution network. Additionally, product liability claims and economic downturns affecting healthcare spending could negatively impact InspireMD's financial performance.
Is NSPR a good stock to buy?
Whether NSPR is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the NSPR MoonshotScore?
The MoonshotScore for NSPR is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is NSPR data updated?
NSPR stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to NSPR is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for NSPR?
Growth catalysts for InspireMD, Inc. (NSPR) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes InspireMD, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are NSPR's main competitors?
InspireMD, Inc. (NSPR) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether NSPR has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about NSPR?
Wall Street analyst coverage for NSPR includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is NSPR's market cap?
Market capitalization (market cap) for NSPR is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows NSPR's current market cap alongside enterprise value and other valuation metrics.
How has NSPR stock performed recently?
NSPR's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing NSPR's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in NSPR?
Key risk categories for NSPR include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures NSPR's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling NSPR?
Insider trading activity for NSPR tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is NSPR a good stock for beginners?
InspireMD, Inc. (NSPR) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is NSPR for first-time investors?
Every stock carries risk, including InspireMD, Inc. (NSPR). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like NSPR.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Financial data is limited and may not be fully up-to-date. Future performance is subject to market conditions and company execution.